Core needle biopsy blocks were tested. For tumors with RS < 11, patients received hormonal therapy (NHT); patients with RS > 25 tumors received chemotherapy (NCT); patients with RS 11-25 were randomized to NHT or NCT. Primary endpoint was whether 1/3 or more of randomized patients refused assigned treatment.
While hormone receptor positive (HR+) cancers do respond to neoadjuvant chemotherapy (NCT), pathologic complete responses (pCR) are infrequent reaching only 10-15% in most trials. 4, 6, 7 Neoadjuvant hormonal therapy (NHT), on other hand, may make BCS possible with less toxicity than NCT, and it has been shown to induce objective responses in more than two-thirds of selected patients with HR+ cancers. [8] [9] [10] A recent meta-analysis of studies including NHT concluded that NHT was equally effective for selected HR+ breast cancers as NCT. 9 However, particularly in the United States, NCT is the standard approach for appropriate patients and NHT is seldom utilized.
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A review of data from the National Cancer Data Base found that from 2004 to 2012, less than 3% of patients 50 years of age or older who had T2-T4 HR+ breast cancers received NHT. 12 Even after the publication of the Z1031 trial data, 8 the use of NHT has not changed significantly.
In addition to HR status and histopathologic tumor type, multiple studies have recently shown that gene expression profiles, either microarray-based or RT-PCR based, can predict prognosis as well as the likelihood of responsiveness to chemotherapy. 13, 14 These assays were first and St. Gallen 17-21 recommended adjuvant chemotherapy be given to patients with HR+, node-negative, early-stage breast cancer, which may account for nearly half of all breast cancer patients in the United States. 22, 23 However, based on the RS result, less than 10-15% of such patients would likely benefit from chemotherapy. 24 Indeed, after more than a decade, the 21-gene RS assay has become widely incorporated into clinical diagnostic work-ups by oncologists and their patients to inform decisions about adjuvant chemotherapy. 16, [25] [26] [27] [28] [29] [30] [31] Additional data from the SWOG 8814 trial suggest that the RS may also predict the likelihood of benefit from chemotherapy, even for patients with nodal metastases. 32 Recently, there have been multiple small studies incorporating the RS in the neoadjuvant setting. These studies have shown that pCR or clinical complete response (cCR) to chemotherapy almost never occurs in patients with a low RS. 13, 14, 33, 34 Furthermore, others have shown that clinical responses with NHT are more likely if the patients have a low RS. 35, 36 This fits well with the finding from the NSABP B-14 study
showing that a low RS predicted the greatest benefit from adjuvant treatment with tamoxifen as well as the results of the B-20 study showing the absence of benefit from chemotherapy in patients with a low RS. 16, 27 While similar observations have also been seen with other tests, including the 70-gene profile and the PAM-50 assays, based on intrinsic subtypes, neither of these two assays has formally demonstrated that the assay result predicts the likelihood of chemotherapy benefit in any setting (adjuvant or neoadjuvant). [37] [38] [39] One early report using the PAM-50 assay to define intrinsic subtype showed that there was some indication that luminal A patients had little chance of a pCR with chemotherapy, but still had a good prognosis; luminal B tumors, on the other hand, were also unlikely to respond well to chemotherapy, but had a worse prognosis. 
| Study design
The protocol was approved by each of the seven local human investigations committees or IRBs, with assurances filed with and approved by the U.S.
Department of Health and Human Services. Written informed consent was
obtained from all individual participants included in the study.
The study schema is shown in Fig. 1 . Tissue blocks from the biopsies were sent to the Genomic Health laboratory (Clinical Laboratory Improvement Amendments certified) for RS testing according to standard procedures. 16 Treatment was assigned based on the RS result: patients with RS < 11 were to receive NHT; patients with RS > 26 were to receive NCT;
patients with midrange RS = 11-25 were randomized to NHT or NCT.
The primary objective was determining the feasibility of randomizing patients with midrange RS values (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) between NHT and NCT. The primary endpoint was to determine whether onethird or more of randomized patients would refuse assigned treatment.
Secondary endpoints included: clinical partial and complete response (cPR, cCR) rates using RECIST criteria by either ultrasound or physical exam (using the same method as was used at baseline), overall clinical response rates, pCR in the breast (defined as no histologic evidence of invasive tumor cells in the surgical breast specimen), pCR in the breast and nodes, and successful BCS (partial mastectomy with negative margins followed by radiation therapy).
Patients who were considered potential candidates for BCS were to have the primary tumor site marked in some way prior to initiating chemotherapy or, at least, prior to disappearance of the tumor clinically.
This could be achieved with insertion of a radiopaque marker or clip, tattoos of the tumor boundary on the skin (especially for smaller breasts), or by making a transparent template with the tumor site marked on it.
Other techniques were acceptable, as long as they provided assurance that the primary tumor site could be located and excised. If a clip was used, a specimen radiograph was to be performed to confirm its removal. For patients assigned to NHT, tamoxifen was used for pre-menopausal women and an aromatase inhibitor (choice of which one up to the investigator) for post-menopausal women. Treatment was to continue for 4-6 months, with at least monthly assessments of response, followed by surgery. If tumor progression was noted at any time, the patient could be taken to surgery immediately or switched to cytotoxic chemotherapy at the investigator's discretion. For patients assigned to NCT, the regimen was chosen at the treating oncologist's discretion, but in general an anthracycline/taxane based regimen, with 6-8 courses of therapy lasting 4-6 months was recommended. Response to therapy was to be assessed prior to each course of therapy. If tumor progression was noted at any time during the first therapeutic regimen, then, the patient could either be switched to the second planned regimen or could be taken to surgery immediately. If progression occurred during the second regimen, the patient was generally taken to surgery.
Postoperative adjuvant therapy for all subjects was at the discretion of the investigator/treating physician. Adjuvant chemotherapy could be given, using any regimen considered appropriate, generally before irradiation or starting hormonal adjuvant therapy. For all patients, regardless of neoadjuvant therapy, hormonal therapy was to be administered after surgery, chemotherapy (if given), and radiation (if given) for a total of at least 5 years.
| Statistical methods
To avoid possible confounding effects and ensure adequate balance between the two treatment groups (hormonal vs cytotoxic therapy), randomization was stratified by site. To avoid possible risk for selection bias, a blocked randomization scheme with randomly permuted block sizes (unknown to the investigators) was conducted. The randomization list was generated by the study biostatistician (WW). A random number generator was used to generate a random sequence of the two assignments. The treatment assignments were sealed in envelopes, ordered according to the sequence generated and placed securely in the research nurse's office. were used to compare the four treatment groups for the secondary endpoints. 43 To compare the four groups in terms of each of the clinical characteristics, the Fisher's exact test (for race, menopausal status, T-stage, N-stage, ER, PR, and tumor grade) and the Kruskal-Wallis test (for age and baseline tumor size) were used. All statistical analyses were performed in SAS 9.4, and all statistical testing was two-sided and considered significant if a P-value was smaller than the type I error of 5%.
| RESULTS
Seven U.S. and Canadian centers enrolled sixty-four patients: five were excluded (one delay in RS result, one tissue block lost at participating center, one HR testing discrepancy, two deemed not eligible [one for no FIGURE 3 Distribution of patients according to their RS values: based on "standard" cutoffs (A) and cutoffs used to allocate patients in this study (B) NCT, the breast pCR rate was 21.4% and breast plus nodes pCR rate was 14.3%. None of the other groups had a pCR for the breast plus nodes. Importantly, greater than 70% of the patients in the groups A and B who were treated with NHT achieved successful BCS. Fewer, but still a majority of patients in groups C (63.6%) and D (57.1%) who were treated with NCT achieved BCS successfully.
| DISCUSSION
The molecular profiling of breast cancers has now become common practice as a tool for making decisions on whether to use adjuvant chemotherapy after surgery, especially for node-negative and HR+ cancers. A number of different molecular profiles are now commercially available. As of December 2016, the Oncotype Dx assay had been performed over 600 000 times, and approximately 20% of the specimens have been core needle biopsies (personal communication from AS at GHI).
When the RS assay is run on core biopsy samples, there is a greater than 90% success rate for generating a RS. Presumably, the purpose of most of these specimen submissions was to make a pre-operative decision about 
| CONCLUSIONS
This pilot study demonstrates the feasibility of using the RS to guide NST, with only a 15% refusal rate of assigned treatment in patients with an RS of 11-25. Prospective demonstration that the RS can provide value in neoadjuvant decision making and thus safely and effectively spare patients exposure to the cost and toxicity of chemotherapy is an essential step toward further personalizing care
while not sacrificing outcomes. Furthermore, although patients who had an RS of 11-25 and received NHT had a lower rate of objective clinical responses, the rate of successful BCS (>70%) was similar to the patients with an RS of less than 11 and to patients with an RS of 11-25 treated with chemotherapy. None of the patients with an RS of [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] who received NCT had a pCR. These findings should enable physicians to have greater confidence in the value of NHT. These results demonstrate that conducting a similarly designed larger trial is feasible and suggests that for patients with an RS of 25 or less, NHT is a potentially effective strategy. They also support the use of the RS to identify appropriate patients for NCT versus NHT, similar to its previously validated value in the adjuvant setting.
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